Cargando…
Markers of Antioxidant Defense in Patients with Type 2 Diabetes
Aims. Diabetes is considered a state of increased oxidative stress. This study evaluates blood concentrations of selected markers of antioxidant defense in patients with type 2 diabetes. Methods. The study included 80 type 2 diabetes patients and 79 apparently healthy controls. Measured markers incl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657103/ https://www.ncbi.nlm.nih.gov/pubmed/26640613 http://dx.doi.org/10.1155/2016/2352361 |
_version_ | 1782402337261748224 |
---|---|
author | Gawlik, K. Naskalski, J. W. Fedak, D. Pawlica-Gosiewska, D. Grudzień, U. Dumnicka, P. Małecki, M. T. Solnica, B. |
author_facet | Gawlik, K. Naskalski, J. W. Fedak, D. Pawlica-Gosiewska, D. Grudzień, U. Dumnicka, P. Małecki, M. T. Solnica, B. |
author_sort | Gawlik, K. |
collection | PubMed |
description | Aims. Diabetes is considered a state of increased oxidative stress. This study evaluates blood concentrations of selected markers of antioxidant defense in patients with type 2 diabetes. Methods. The study included 80 type 2 diabetes patients and 79 apparently healthy controls. Measured markers included ferric reducing ability of plasma (FRAP), reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), γ-glutamyltransferase (GGT) and uric acid serum, and plasma and/or hemolysate levels. Results. FRAP, uric acid, CRP, and GGT levels were significantly higher in patients with diabetes. Plasma and hemolysate GR was significantly higher whereas GPx activity was significantly lower in patients with diabetes. There were no significant differences in antioxidant defense markers between patients with and without chronic diabetes complications. Fasting serum glucose correlated with plasma GPx, plasma and hemolysate GR, FRAP, and serum GGT, and HbA1c correlated with serum GGT. Only FRAP and serum uric acid were significantly higher in obese (BMI > 30 kg/m(2)) patients with diabetes than in nonobese patients. Conclusions. Some components of antioxidant defense such as GR, uric acid, and GGT are increased in patients with type 2 diabetes. However, the whole system cannot compensate for an enhanced production of ROS as reflected by the trend toward decreased erythrocytes GSH. |
format | Online Article Text |
id | pubmed-4657103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-46571032015-12-06 Markers of Antioxidant Defense in Patients with Type 2 Diabetes Gawlik, K. Naskalski, J. W. Fedak, D. Pawlica-Gosiewska, D. Grudzień, U. Dumnicka, P. Małecki, M. T. Solnica, B. Oxid Med Cell Longev Research Article Aims. Diabetes is considered a state of increased oxidative stress. This study evaluates blood concentrations of selected markers of antioxidant defense in patients with type 2 diabetes. Methods. The study included 80 type 2 diabetes patients and 79 apparently healthy controls. Measured markers included ferric reducing ability of plasma (FRAP), reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), γ-glutamyltransferase (GGT) and uric acid serum, and plasma and/or hemolysate levels. Results. FRAP, uric acid, CRP, and GGT levels were significantly higher in patients with diabetes. Plasma and hemolysate GR was significantly higher whereas GPx activity was significantly lower in patients with diabetes. There were no significant differences in antioxidant defense markers between patients with and without chronic diabetes complications. Fasting serum glucose correlated with plasma GPx, plasma and hemolysate GR, FRAP, and serum GGT, and HbA1c correlated with serum GGT. Only FRAP and serum uric acid were significantly higher in obese (BMI > 30 kg/m(2)) patients with diabetes than in nonobese patients. Conclusions. Some components of antioxidant defense such as GR, uric acid, and GGT are increased in patients with type 2 diabetes. However, the whole system cannot compensate for an enhanced production of ROS as reflected by the trend toward decreased erythrocytes GSH. Hindawi Publishing Corporation 2016 2015-11-10 /pmc/articles/PMC4657103/ /pubmed/26640613 http://dx.doi.org/10.1155/2016/2352361 Text en Copyright © 2016 K. Gawlik et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Gawlik, K. Naskalski, J. W. Fedak, D. Pawlica-Gosiewska, D. Grudzień, U. Dumnicka, P. Małecki, M. T. Solnica, B. Markers of Antioxidant Defense in Patients with Type 2 Diabetes |
title | Markers of Antioxidant Defense in Patients with Type 2 Diabetes |
title_full | Markers of Antioxidant Defense in Patients with Type 2 Diabetes |
title_fullStr | Markers of Antioxidant Defense in Patients with Type 2 Diabetes |
title_full_unstemmed | Markers of Antioxidant Defense in Patients with Type 2 Diabetes |
title_short | Markers of Antioxidant Defense in Patients with Type 2 Diabetes |
title_sort | markers of antioxidant defense in patients with type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657103/ https://www.ncbi.nlm.nih.gov/pubmed/26640613 http://dx.doi.org/10.1155/2016/2352361 |
work_keys_str_mv | AT gawlikk markersofantioxidantdefenseinpatientswithtype2diabetes AT naskalskijw markersofantioxidantdefenseinpatientswithtype2diabetes AT fedakd markersofantioxidantdefenseinpatientswithtype2diabetes AT pawlicagosiewskad markersofantioxidantdefenseinpatientswithtype2diabetes AT grudzienu markersofantioxidantdefenseinpatientswithtype2diabetes AT dumnickap markersofantioxidantdefenseinpatientswithtype2diabetes AT małeckimt markersofantioxidantdefenseinpatientswithtype2diabetes AT solnicab markersofantioxidantdefenseinpatientswithtype2diabetes |